XML 43 R44.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of the Net Purchase Price and Allocation to the Acquired Assets (Detail) - ProstaGene, LLC - USD ($)
9 Months Ended
Feb. 29, 2020
May 31, 2019
Business Acquisition, Contingent Consideration [Line Items]    
CytoDyn Inc. Equity $ 11,558,000  
Acquisition Expenses 741,297  
Release of Deferred Tax Asset 2,826,919  
Total Cost of Acquisition 15,126,216  
Intangible assets 15,126,216 $ 15,126,216
Other 0  
Allocation of Acquisition Costs $ 15,126,216